Advertisement

Medical Oncology

, Volume 18, Issue 2, pp 141–148 | Cite as

Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma

Evaluation of safety and efficacy in a multicenter study
  • J. Walewski
  • E. Kraszewska
  • O. Mioduszewska
  • J. Romejko-Jarosińska
  • A. Hellmann
  • J. Czyż
  • J. Hołowiecki
  • M. Kopera
  • S. Grosicki
  • M. Komarnicki
  • L. Rumianowski
  • K. Kuliczkowski
  • T. Wróbel
  • J. Dwilewicz-Trojaczek
  • T. Robak
  • K. Warzocha
  • J. Załuski
  • E. Wójcik
  • A. Dmoszyńska
  • A. Walter-Croneck
  • the Polish Lymphoma Research Group
Original Article

Abstract

The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses in patients with recurrent indolent lymphoma. Thirty-eight patients entered into this study, 63% had follicular lymphoma and 61% had an IPI score of 2 or more. Median disease duration was 3 yr, median number of prior treatments was three, and 66% of patients responded to the immediate past treatment with a median remission duration of 3 mo. A total of 158 antibody doses were given, including two patients who received two courses of four infusions each. One patient developed acute respiratory failure after the second dose and required assisted ventilation. There was no immediate relationship to the antibody infusion and no evidence of infection. This complication resolved and the patient successfully completed the full course of the antibody treatment. Another patient discontinued therapy after the second dose owing to intolerable fever and painful erythema. Sixty percent of the first, and 20% of subsequent rituximab infusions were associated with infusion-related reactions including mild fever, chills, and occasional skin eruptions. Complete and partial responses were achieved in 24% and 35% of 34 evaluable patients, respectively, for an overall response rate of 59%. The median time to progression/relapse in responding patients was 16 mo (95% CI, 6.4, 25.6) compared with a median of 3 mo duration of response to the immediate previous therapy in these patients. Longer response duration post rituximab monotherapy than with previous treatment in this series of heavily pretreated patients suggests a major role for the antibody in the therapy of patients with indolent lymphoma.

Key Words

Anti-CD20 antibody follicular lymphoma relapse remission duration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vose JM. 1999. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 36 (Suppl 6): 15–20.PubMedGoogle Scholar
  2. 2.
    Horning SJ. 1993. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 20 (Suppl 5): 75–88.PubMedGoogle Scholar
  3. 3.
    Lopez-Guillermo A, et al. 1994. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphomas. J Clin Oncol 12: 1343–1348.PubMedGoogle Scholar
  4. 4.
    The Non-Hodgkin’s Lymphoma Classification Project. 1997. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89: 3909–3918.Google Scholar
  5. 5.
    Pigaditou A, et al. 1993. Fludarabine in low-grade lymphoma. Semin Oncol 20 (Suppl 7): 24–27.PubMedGoogle Scholar
  6. 6.
    Robak T, et al. 1997. Activity of 2 chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 26: 99.PubMedGoogle Scholar
  7. 7.
    Miller RA, Maloney DG, Warnke R, Levy R. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Eng J Med 306: 517–520.CrossRefGoogle Scholar
  8. 8.
    Maloney DG, et al. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90: 2188–2195.PubMedGoogle Scholar
  9. 9.
    McLaughlin P, et al. 1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for replased indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825–2833.PubMedGoogle Scholar
  10. 10.
    Winkler U, et al. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217–2224.PubMedGoogle Scholar
  11. 11.
    Kaplan EL, Meier P. 1958. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457–481.CrossRefGoogle Scholar
  12. 12.
    Cox DR. 1972. Regression models and life tables. J R Stat Soc B 34: 187–220.Google Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  • J. Walewski
    • 1
  • E. Kraszewska
    • 1
  • O. Mioduszewska
    • 1
  • J. Romejko-Jarosińska
    • 1
  • A. Hellmann
    • 2
  • J. Czyż
    • 2
  • J. Hołowiecki
    • 3
  • M. Kopera
    • 3
  • S. Grosicki
    • 4
  • M. Komarnicki
    • 4
  • L. Rumianowski
    • 4
  • K. Kuliczkowski
    • 5
  • T. Wróbel
    • 5
  • J. Dwilewicz-Trojaczek
    • 5
  • T. Robak
    • 5
  • K. Warzocha
    • 5
  • J. Załuski
    • 6
  • E. Wójcik
    • 6
  • A. Dmoszyńska
    • 7
  • A. Walter-Croneck
    • 7
  • the Polish Lymphoma Research Group
  1. 1.The Maria Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarszawa
  2. 2.Department of HematologyUniversity School of MedicineGdansk
  3. 3.Department of Hematology and Bone Marrow TransplantationSilesian University School of MedicineKatowice
  4. 4.Department of OncologyUniversity School of MedicinePoznan
  5. 5.Department of Hematology, OncologyUniversity School of MedicineWarsaw
  6. 6.Department of Medical OncologyGreatpoland Cancer CenterPoznan
  7. 7.Department of HematologyUniversity School of MedicineLublinPoland

Personalised recommendations